Showing 461 - 479 results of 479 for search 'per monitoring (programme OR programs)', query time: 0.14s Refine Results
  1. 461

    Innovation Ecosystem of Iran's Tourism Industry with Emphasis on Supply Chain by Azizolah Jafari, mahdi alaei kerahrudi

    Published 2024-01-01
    “…The growth of social groups on the Internet has created dynamic sources of opinions and recommendations, forming virtual tourism programs that challenge traditional service providers, especially in adventure tourism. …”
    Get full text
    Article
  2. 462
  3. 463

    Relationship between physical activity and abdominal obesity and metabolic markers in postmenopausal women by Yangjun Liu, Sujie Mao, Wei Xie, Humińska-Lisowska Kinga Agnieszka, Sawczyn Monika Helena, Dzitkowska-Zabielska Magdalena, Guoping Qian, Zbigniew Ossowski

    Published 2024-11-01
    “…Was included 71 participants from this study program (68.8 ± 4.3 years). We divided participants into LPA and MVPA groups based on their level of moderate to vigorous physical activity per week; Physical activity levels over 7 days were assessed using a POLAR accelerometer, with daily step counts and sedentary time recorded. …”
    Get full text
    Article
  4. 464
  5. 465

    RICD: Russian Intensive Care Dataset by A. V. Grechko, M. Y. Yadgarov, A. A. Yakovlev, L. B. Berikashvili, A. N. Kuzovlev, P. A. Polyakov, I. V. Kuznetsov, V. V. Likhvantsev

    Published 2024-06-01
    “…RICD also contains data on several vital parameters collected from bedside monitors and other equipment of ICUs, with up to 10 evaluations per hour.Conclusion. …”
    Get full text
    Article
  6. 466

    Focused low-intensity hippocampal transcranial ultrasound stimulation (TUS) for sleep disturbances in patients with chronic tinnitus: A study protocol for a pilot randomized contro... by Xi Ni, Yuk Shan Yuen, Zeyan Li, Kaipeng Wang, Natalie Shu Yang, Yi Yuan, Lin Meng, Liwei Guo, Hanna Lu

    Published 2025-01-01
    “…Participants' adherence to the program and any adverse event will be closely monitored throughout the duration of the clinical trial.…”
    Get full text
    Article
  7. 467
  8. 468
  9. 469

    Effects of three months of water-based exercise training on metabolic syndrome components in older women (Efecto de tres meses de entrenamiento con ejercicios acuáticos sobre comp... by Paulina Yesica Ochoa-Martínez, Javier Arturo Hall-López, Daniel Piña Diaz, Diego Armando Zarate Trujillo, Ana Maria Teixeira

    Published 2019-01-01
    “…The training protocol consisted of water-based exercise training sessions 5 times per week during 12 weeks of intervention, executed in a pool of 1.3 meters divided into three phases: a 10-minute warm-up, 30 minutes of aerobic exercise at 50%-60% of maximum heart rate (monitored by heart rate monitor) and a 10 minute cool down. …”
    Get full text
    Article
  10. 470

    p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis by Celine I. Wittke, Eric C. Cheung, Dimitris Athineos, Nicola Clements, Liam Butler, Mark Hughes, Vivienne Morrison, Dale M. Watt, Karen Blyth, Karen H. Vousden, Timothy J. Humpton

    Published 2025-07-01
    “…Background & Aims: TP53 is a potent tumour suppressor that coordinates diverse stress response programmes, ranging from pro-survival activities to cell death. p53 is also engaged during tissue damage and repair, including within the liver. …”
    Get full text
    Article
  11. 471

    Effect of Telemedicine Interventions on Heart Failure Hospitalizations: A Randomized Trial by Edmar G. Ribeiro, Luisa C. C. Brant, Lilian C. Rezende, Regina Bernal, Graziela Chequer, Barbara V. Temponi, Daniel B. Vilela, Julia B. Buback, Renato D. Lopes, Tulio B. Franco, Antonio L. P. Ribeiro, Deborah C. Malta

    Published 2025-03-01
    “…Results were consistent in “per‐protocol” and subgroup analyses. Enrollment was lower than expected because of COVID‐19 disruptions. …”
    Get full text
    Article
  12. 472
  13. 473
  14. 474

    Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study by Lin Shen, Qing Zhou, Ting Sun, Jie Wang, Hongming Pan, Yi-Long Wu, Jun Zhao, Jun Guo, Qingyuan Zhang, Ying Yuan, Yuxian Bai, Tianshu Liu, Yongqian Shu, Siyang Wang, Aiping Zhou, Dingwei Ye, Yujuan Gao, Silu Yang, Zuobai Wang

    Published 2020-05-01
    “…Patients previously treated with therapies targeting PD-1 or its ligand, programmed cell death ligand-1 were excluded. During dose-verification, dose-limiting toxicities (DLTs) were monitored; safety and tolerability were examined and the previously determined recommended phase 2 dose (RP2D) was verified. …”
    Get full text
    Article
  15. 475

    Better public housing management in Ghana by Samson Aziabah

    Published 2018-04-01
    “…It also builds on knowledge of lesson drawing and the transferability of programmes (see Rose, 2001) from one context to another. …”
    Get full text
    Article
  16. 476
  17. 477

    Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context by Suying Lu, Yi Que, Dongyang Liu, Feifei Sun, Xueting Yao, Liting Deng, Jing Zhan, Junting Huang, Ruiqing Cai, Xin Wang, Shixing Zhu, Zijun Zhen, Jia Zhu, Juan Wang, Yizhuo Zhang

    Published 2025-06-01
    “…The primary analysis included all participants who received at least one dose of anlotinib, following the per protocol approach. The safety analysis included all participants who received at least one dose of anlotinib and were monitored for adverse events during the treatment period. …”
    Get full text
    Article
  18. 478
  19. 479

    Global Carbon Budget 2024 by P. Friedlingstein, P. Friedlingstein, M. O'Sullivan, M. W. Jones, R. M. Andrew, J. Hauck, J. Hauck, P. Landschützer, C. Le Quéré, H. Li, H. Li, I. T. Luijkx, A. Olsen, A. Olsen, G. P. Peters, W. Peters, W. Peters, J. Pongratz, J. Pongratz, C. Schwingshackl, S. Sitch, J. G. Canadell, P. Ciais, R. B. Jackson, R. B. Jackson, S. R. Alin, A. Arneth, V. Arora, N. R. Bates, M. Becker, M. Becker, N. Bellouin, C. F. Berghoff, H. C. Bittig, L. Bopp, P. Cadule, K. Campbell, M. A. Chamberlain, N. Chandra, F. Chevallier, L. P. Chini, T. Colligan, J. Decayeux, L. M. Djeutchouang, L. M. Djeutchouang, X. Dou, C. Duran Rojas, K. Enyo, W. Evans, A. R. Fay, R. A. Feely, D. J. Ford, A. Foster, T. Gasser, M. Gehlen, T. Gkritzalis, G. Grassi, L. Gregor, N. Gruber, Ö. Gürses, I. Harris, M. Hefner, M. Hefner, J. Heinke, G. C. Hurtt, Y. Iida, T. Ilyina, T. Ilyina, T. Ilyina, A. R. Jacobson, A. R. Jacobson, A. K. Jain, T. Jarníková, A. Jersild, F. Jiang, Z. Jin, Z. Jin, E. Kato, R. F. Keeling, K. Klein Goldewijk, J. Knauer, J. Knauer, J. I. Korsbakken, X. Lan, X. Lan, S. K. Lauvset, S. K. Lauvset, N. Lefèvre, Z. Liu, J. Liu, J. Liu, L. Ma, S. Maksyutov, G. Marland, G. Marland, N. Mayot, P. C. McGuire, N. Metzl, N. M. Monacci, E. J. Morgan, S.-I. Nakaoka, C. Neill, Y. Niwa, T. Nützel, L. Olivier, L. Olivier, T. Ono, P. I. Palmer, P. I. Palmer, D. Pierrot, Z. Qin, L. Resplandy, L. Resplandy, A. Roobaert, T. M. Rosan, C. Rödenbeck, J. Schwinger, J. Schwinger, T. L. Smallman, T. L. Smallman, S. M. Smith, R. Sospedra-Alfonso, T. Steinhoff, T. Steinhoff, Q. Sun, A. J. Sutton, R. Séférian, S. Takao, H. Tatebe, H. Tatebe, H. Tian, B. Tilbrook, B. Tilbrook, O. Torres, E. Tourigny, H. Tsujino, F. Tubiello, G. van der Werf, R. Wanninkhof, X. Wang, D. Yang, X. Yang, Z. Yu, W. Yuan, X. Yue, S. Zaehle, N. Zeng, N. Zeng, J. Zeng

    Published 2025-03-01
    Get full text
    Article